Bayer's drugs unit secures Q2 earnings beat

FRANKFURT, July 27 (Reuters) - Bayer, the German

drugmaker trying to acquire U.S. seed company Monsanto,

easily surpassed second-quarter earnings expectations and raised

its full-year guidance on strong gains in stroke prevention pill

Xarelto and anti-blindness drug Eylea.

Read more